Last reviewed 2026-05-28 · How we verify

Raloxifene - Usual

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Phase 2 active Small molecule ✓ Verified May 2026

Raloxifene - Usual is a Small molecule drug developed by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. It is currently in Phase 2 development. Also known as: Raloxifene Chemotherapy (Generic-1).

Raloxifene is a small molecule that modulates the estrogen receptor beta, classified as a MODULATOR. It is used to treat conditions such as osteoporosis and postmenopausal symptoms, and has also been studied in relation to breast cancer.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Raloxifene - Usual
Also known as	Raloxifene Chemotherapy (Generic-1)
Sponsor	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Raloxifene - Usual CI brief — competitive landscape report
Raloxifene - Usual updates RSS · CI watch RSS
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair portfolio CI

Frequently asked questions about Raloxifene - Usual

What is Raloxifene - Usual?

Raloxifene - Usual is a Small molecule drug developed by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

Who makes Raloxifene - Usual?

Raloxifene - Usual is developed by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (see full Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair pipeline at /company/han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair).

Is Raloxifene - Usual also known as anything else?

Raloxifene - Usual is also known as Raloxifene Chemotherapy (Generic-1).

What development phase is Raloxifene - Usual in?

Raloxifene - Usual is in Phase 2.

Manufacturer: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — full pipeline
Also known as: Raloxifene Chemotherapy (Generic-1)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing